Wockhardt Limited
Investor Presentation By
- Dr. Murtaza Khorakiwala
Managing Director Oct 2013
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala - - PowerPoint PPT Presentation
Wockhardt Limited Investor Presentation By Dr. Murtaza Khorakiwala Managing Director Oct 2013 Safe Harbor Statement Except for historical information contained herein, statements in this communication, which include words or phrases such
Investor Presentation By
Managing Director Oct 2013
words or phrases such as “will”, “aim”, “will likely result”, “would”, “believe”, “may”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “likely”, “project”, “should”, “potential”, “will pursue” and similar expressions or variations of such expressions may constitute “forward looking statements”. These forward looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward looking statements. These risks and uncertainties include, but are not limited to our ability to successfully implement our strategy, our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological changes, investment and business income, cash flow projections, our exposure to market risks as well as other
reflect events or circumstances after the date thereof.
Investor Presentation Oct 2013 2
ROW operations Wockhardt Direct
USA UK, Ireland, France, Switz. India
Mexico
Investor Presentation Oct 2013 4
Direct Operations in India, USA and Europe
8600 Associates employed in 21 countries
UK Ireland
Investor Presentation Oct 2013 5
Manufacturing Locations globally
Ankleshwar Daman (2 Plants) Aurangabad (5 Plants) Baddi Chicago
Formulations APIs 9 sites in India
Investor Presentation Oct 2013 6
worldwide
Investor Presentation Oct 2013 10
Investor Presentation Oct 2013 11
Q2FY14 H1FY14 Total No. of Regulatory Inspections 11 12 +ve outcomes (with no or minor observations) 8 9
2 2 Result Awaited 1 1
Investor Presentation Oct 2013 12
by Lachman.
Investor Presentation Oct 2013 13
manufacture of 10 critical products whilst withdrawing the GMP certficate for the said facility.
manufactured at Chikalthana.
being recalled.
Investor Presentation Oct 2013 14
certain critical products whilst it has withdrawn the GMP certificate.
certificate.
Investor Presentation Oct 2013 15
“Critical” or “Major” observations.
were no major observations.
Investor Presentation Oct 2013 16
was completed satisfactorily without any observations.
satisfactorily with few minor observations.
Investor Presentation Oct 2013 18
notification in May 2013.
judice.
Investor Presentation Oct 2013 20
Decline of 11% in Q2FY14 over Q2FY13 Rs.crore
Investor Presentation Oct 2013 21
Rs.crore Declines by 62% in Q2FY14 over Q2FY13
Investor Presentation Oct 2013 22
Rs.crore Declines by 68% in Q2FY14 over Q2FY13
Investor Presentation Oct 2013 23
Investor Presentation Oct 2013 25
Decline of 5% in H1FY14 over H1FY13 Rs.crore
Investor Presentation Oct 2013 26
Declines by 36% in H1FY14 over H1FY13 Rs.crore
Investor Presentation Oct 2013 27
Declines by 39% in H1FY14 over H1FY13 Rs.crore
Investor Presentation Oct 2013 28
Investor Presentation Oct 2013 29
Investor Presentation Oct 2013 30
Q2FY13.
facility.
UK Operations
Grows by 3% (remains flat in £ terms) in H1FY14
Investor Presentation Oct 2013 31
Ireland Operations
Declines by 34% (39% in € terms) over H1FY13.
has impacted the Irish market sales.
Q2FY14 and grows by 1% in H1FY14 in the backdrop of suspension of Dextropropoxyphene and uncertainties due to NLEM issues.
India.
the quarter and by 24% in H1FY14..
Investor Presentation Oct 2013 32
Investor Presentation Oct 2013 33
For investor updates and communication please visit www.wockhardt.com For Information please contact Tushar Mistry Tel.: +91 22 26596210 tmistry@wockhardt.com